GemVax & KAEL Co.,Ltd. Logo

GemVax & KAEL Co.,Ltd.

Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.

082270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노11로 58, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GemVax & KAEL Co., Ltd. is a company with a dual-business structure. Its Environmental Control division manufactures and sells contaminant control solutions, including coating resins and filters, for the semiconductor and display industries. This established business provides the financial foundation for its Bio division, a clinical-stage biopharmaceutical arm focused on developing novel therapeutics. The Bio division's lead candidate is GV1001, a telomerase-derived peptide being developed as a treatment for neurodegenerative diseases, including Alzheimer's disease and Progressive Supranuclear Palsy, and is advancing into late-stage clinical trials.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for GemVax & KAEL Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-17 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 47.6 KB
2025-09-16 00:00
Share Issue/Capital Change
주요사항보고서(제3자의신주인수권부사채매수선택권행사)
Korean 19.5 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.1 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.3 MB
2025-09-05 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.6 KB
2025-09-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 30.2 KB
2025-08-29 00:00
Registration Form
[정정제출요구]증권신고서(지분증권) (2025.11)
Korean 2.9 MB

Automate Your Workflow. Get a real-time feed of all GemVax & KAEL Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GemVax & KAEL Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea 307750
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea 009290
Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine KMED
KYONGBO PHARMACEUTICAL CO., LTD. Logo
Manufactures APIs and finished drugs, offering global CDMO services from development to production.
South Korea 214390
KYORIN Pharmaceutical Co., Ltd. Logo
Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.
Japan 4569
Kyowa Kirin Co.,Ltd. Logo
Develops antibody medicines for oncology, nephrology, immunology, and allergy.
Japan 4151
KyungdongPharm Logo
Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.
South Korea 011040
KYUNG NAM PHARM.CO.,LTD. Logo
South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.
South Korea 053950
Labiana S.A. Logo
Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.
Spain LAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.